Clinical Trial Update: A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial updating on etrolizumab for moderately to severely active Crohn's disease; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Etrolizumab (etrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-11-16